NASDAQ · Biotechnology

DBV Technologies S.A. (DBVT) Stock

$15.84 +0.83% NASDAQ: DBVT Healthcare

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults.

Valuation

MetricValue
Price$15.84
Market Cap$378.92M
P/E Ratio-3.27
P/B Ratio6.53
P/S Ratio595.53
EPS (TTM)$-1.70
52-Week High$26.19
52-Week Low$8.51
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-130.06%
ROA-62.96%
ROCE-80.15%
Gross Margin100.00%
Operating Margin-5311.11%
Net Margin0.00%
Debt/Equity0.03
Current Ratio4.76

Annual Financials (USD)

Metric20212022202320242025
Revenue$6.0M$5.0M$16.0M$0$0
Operating Profit$-99.0M$-97.0M$-76.0M$-121.0M$-147.0M
Net Profit$-98.0M$-96.0M$-73.0M$-114.0M$-147.0M
EPS$-1.80$-1.25$-0.75$-1.20$-1.70
Op Margin-1727.7%-2013.2%-486.0%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$146.0M$247.0M$183.0M$66.0M$234.0M
Total Liabilities$47.0M$52.0M$43.0M$38.0M$65.0M
Cash$77.0M$209.0M$141.0M$32.0M$194.0M
Borrowings$11.0M$4.0M$7.0M$8.0M$22.0M

Latest News

DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 GlobeNewswire · Jul 14, 2026 European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading MT Newswires · Jul 7, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF GlobeNewswire · Jul 6, 2026 European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading MT Newswires · Jul 2, 2026 DBV Expects Viaskin Peanut Patch BLA Submission in Q3 After FDA Feedback MT Newswires · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-108.0M$-56.0M$-80.0M$-104.0M$-121.0M
Investing Cash Flow$-1.0M$-1.0M$-2.0M$-3.0M$-2.0M
Financing Cash Flow$0$0$0$0$-1.0M
Net Cash Flow$-119.0M$132.0M$-68.0M$-109.0M$162.0M
Free Cash Flow$-109.0M$-56.0M$-80.0M$-107.0M$-121.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.19
EV / EBITDA-1.98
FCF Yield-28.37%
Quick Ratio4.76
Interest Coverage-265.45
Return 1Y46.39%
Return 3Y325.15%
Return 5Y50.91%

Ownership

Insiders Held0.00%
Institutions Held37.25%
Institutions Float Held37.25%
Institutional HolderSharesReport Date
MPM Bioimpact LLC5,213,3612026-03-31
Vivo Capital, LLC2,667,5692026-03-31
Artisan Partners Limited Partnership2,219,3862026-03-31
Siren, L.L.C.1,857,3622026-03-31
Baker Bros. Advisors, LP1,461,4252026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALT $3.03 -1.30% -2.31 $267.42M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
ANNX $5.37 +0.75% -3.71 $879.83M 0.00%
ANRO $28.67 +0.70% -6.29 $1.01B 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%

About DBV Technologies S.A.

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.

DBV Technologies S.A. is headquartered in FR.

DBV Technologies S.A. (DBVT) stock trades at $15.84 with a market capitalization of $378.92M. The stock is valued at a price-to-earnings (P/E) ratio of -3.27, price-to-book of 6.53, price-to-sales of 595.53. Over the past 52 weeks the stock has ranged between $8.51 and $26.19, and currently trades 39.5% below its 52-week high.

On profitability, DBV Technologies S.A. generates a return on equity (ROE) of -130.06%, return on capital employed of -80.15%, an operating margin of -5311.11%, a net profit margin of 0.00%.

Official website: www.dbv-technologies.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides